Dynavax Technologies Current Ratio 2010-2022 | DVAX

Dynavax Technologies current ratio from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Dynavax Technologies Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-09-30 $0.93B $0.24B 3.82
2022-06-30 $0.96B $0.35B 2.77
2022-03-31 $0.94B $0.47B 2.02
2021-12-31 $0.97B $0.56B 1.75
2021-09-30 $0.85B $0.53B 1.61
2021-06-30 $0.58B $0.21B 2.85
2021-03-31 $0.43B $0.11B 3.91
2020-12-31 $0.29B $0.08B 3.75
2020-09-30 $0.29B $0.07B 4.35
2020-06-30 $0.27B $0.05B 4.99
2020-03-31 $0.19B $0.03B 6.63
2019-12-31 $0.21B $0.05B 3.93
2019-09-30 $0.23B $0.05B 4.94
2019-06-30 $0.19B $0.05B 4.30
2019-03-31 $0.22B $0.04B 5.27
2018-12-31 $0.17B $0.04B 4.59
2018-09-30 $0.20B $0.03B 6.29
2018-06-30 $0.23B $0.03B 8.87
2018-03-31 $0.26B $0.02B 10.85
2017-12-31 $0.20B $0.02B 10.65
2017-09-30 $0.20B $0.01B 15.29
2017-06-30 $0.13B $0.01B 11.92
2017-03-31 $0.09B $0.01B 7.24
2016-12-31 $0.09B $0.02B 4.47
2016-09-30 $0.12B $0.03B 3.86
2016-06-30 $0.15B $0.03B 5.21
2016-03-31 $0.17B $0.03B 6.97
2015-12-31 $0.20B $0.03B 6.95
2015-09-30 $0.22B $0.02B 11.37
2015-06-30 $0.10B $0.02B 4.46
2015-03-31 $0.10B $0.02B 4.98
2014-12-31 $0.13B $0.02B 6.28
2014-09-30 $0.14B $0.02B 5.91
2014-06-30 $0.16B $0.02B 7.96
2014-03-31 $0.18B $0.02B 11.37
2013-12-31 $0.19B $0.02B 11.88
2013-09-30 $0.08B $0.02B 5.13
2013-06-30 $0.09B $0.02B 6.20
2013-03-31 $0.11B $0.02B 6.34
2012-12-31 $0.13B $0.02B 6.74
2012-09-30 $0.15B $0.03B 5.26
2012-06-30 $0.17B $0.03B 6.56
2012-03-31 $0.11B $0.03B 4.27
2011-12-31 $0.13B $0.03B 4.58
2011-09-30 $0.06B $0.01B 5.51
2011-06-30 $0.07B $0.01B 6.29
2011-03-31 $0.06B $0.01B 4.87
2010-12-31 $0.08B $0.01B 5.35
2010-09-30 $0.05B $0.02B 2.39
2010-06-30 $0.06B $0.03B 2.07
2010-03-31 $0.03B $0.02B 2.00
2009-12-31 $0.04B $0.01B 2.64
2009-09-30 $0.05B $0.01B 4.28
2009-06-30 $0.06B $0.01B 4.88
2009-03-31 $0.07B $0.02B 2.70
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.503B $0.439B
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00